Publications by authors named "M Pegram"
Article Synopsis
- The Breast Cancer Index (BCI) assay helps assess late recurrence risk and inform decisions about extended endocrine therapy (EET) in early-stage breast cancer patients.
- Analysis of data from the BCI Registry showed significant changes in both physician recommendations and patient preferences regarding EET after BCI testing.
- Post-BCI testing, many patients felt more informed and confident about their treatment choices, with reduced concerns about costs and drug safety.
The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Primary analysis confirmed CNS objective response rate (ORR) was 11% (95% confidence interval [CI]: 3-25); clinical benefit rate (CBR) was 68% (4 months) and 51% (6 months). We report final efficacy data after a further 21-months of follow-up, updated safety, survival, and patient-reported outcomes (PROs).
View Article and Find Full Text PDFArticle Synopsis
- Hormone receptor-positive (HR+)/HER2+ breast cancer is a specific type of breast cancer that makes up about 10% of cases in the U.S. and involves certain proteins that can affect treatment options.
- Current treatments use a combination of special antibodies and chemotherapy, which work well for some patients, but researchers are looking for other targeted treatments because tumors can vary and might resist standard therapies.
- Scientists are also exploring ways to block other pathways in the cancer cell to make treatments more effective, including potential new medicines that could work alongside existing therapies.
Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient's optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including multigene assays, which can estimate risk of recurrence and quantify the potential benefit of different adjuvant treatment modalities. While the tools endorsed by treatment guidelines are supported by level I and II evidence and provide similar prognostic accuracy at the population level, they can yield discordant risk prediction at the individual patient level.
View Article and Find Full Text PDFThe human epidermal growth factor receptor 2 (HER2) is overexpressed in 13-22% of breast cancers (BC). Approximately 60-70% of HER2+ BC co-express hormone receptors (HRs). HR/HER2 co-expression modulates response to both anti-HER2-directed and endocrine therapy due to "crosstalk" between the estrogen receptor (ER) and HER2 pathways.
View Article and Find Full Text PDF